Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $30.47 ($460K) on 2026-01-02, disclosed to the SEC on 2026-01-06.
Scheduled sale ($460k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.47 | 12,709 | $387K | 84.2% |
| 2 | $31.79 | 2,191 | $70K | 15.1% |
| 3 | $32.39 | 100 | $3K | 0.7% |
| Total | $30.68 avg | 15,000 | $460K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |